🇺🇸 Mixtard 30:70 Novonordisk® twice daily in United States

Mixtard 30:70 Novonordisk® twice daily (Mixtard 30:70 Novonordisk® twice daily) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Mixtard 30:70 Novonordisk® twice daily in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Mixtard 30:70 Novonordisk® twice daily approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Mixtard 30:70 Novonordisk® twice daily in United States?

Hospital Universitario Central de Asturias is the originator. The local marketing authorisation holder may differ — check the official source linked above.